This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intravitreal Bevacizumab for Age-Related Macular Degeneration

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
Information provided by:
Asociación para Evitar la Ceguera en México Identifier:
First received: June 29, 2006
Last updated: June 30, 2006
Last verified: June 2006
The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration

Condition Intervention Phase
Age Related Macular Degeneration Drug: bevacizumab intravitreal injection Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intravitreal Bevacizumab Therapy for Neovascular Age-Related Macular Degeneration: A Pilot Study

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Improvement of visual acuity at 6 months

Secondary Outcome Measures:
  • Retinal thickness at 6 months
  • Leakiness in fluorangiography at 6 months

Estimated Enrollment: 50
Study Start Date: September 2005
Estimated Study Completion Date: September 2006
Detailed Description:

The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined.

The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age >50 age related macular degeneration

Exclusion Criteria:

  • moderate to severe cataract glaucoma intraocular surgery diabetes mellitus non controlled hypertension coronary artery disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00347165

Hospital Luis Sanchez Bulnes Recruiting
MExico city, DF, Mexico, 04030
Contact: Hugo Quiroz-Mercado, MD    525510841400 ext 1171   
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Study Chair: Hugo Quiroz-Mercado, MD Asociación para Evitar la Ceguera en México
  More Information

Publications: Identifier: NCT00347165     History of Changes
Other Study ID Numbers: AvastinDMRE
Study First Received: June 29, 2006
Last Updated: June 30, 2006

Keywords provided by Asociación para Evitar la Ceguera en México:
macular degeneration

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on August 18, 2017